Akari Therapeutics (AKTX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
13 Feb, 2026Payload innovation and scientific differentiation
PH1 payload targets RNA splicing, inducing potent cytotoxicity and activating both innate and adaptive immunity, with a differentiated safety profile compared to existing ADCs.
Unique mechanism increases mis-spliced RNAs, leading to cell death and immune activation via protein neoantigens.
Preclinical data show superior tumor regression and immune response versus leading Trop-2 ADCs, with reduced off-target effects due to a proprietary non-cleavable linker.
No neutropenia, mucositis, or interstitial lung disease observed in non-human primate studies; safety findings are manageable and reversible.
Lead program and clinical development
Lead candidate AKTX-101 (Trop-2 PH1 ADC) is entering IND-enabling studies, with Phase 1 filing expected in Q4 2026 and first-in-human trial start in ~12 months.
Initial clinical focus is on urothelial cancer, with rapid expansion planned into other Trop-2 expressing solid tumors such as gastric, lung, and breast cancers.
Phase 1a/1b trial will assess safety, dosing, and early efficacy in multiple tumor types, with initial data expected 18 months from trial start.
AKTX-101 has demonstrated significant preclinical activity in aggressive urothelial cancer models, outperforming standard therapies.
Market opportunity and value proposition
Large addressable market across multiple solid tumors expressing Trop-2, with significant unmet needs in urothelial cancer.
Second-line urothelial cancer represents a valuable entry point, with 75,000 patients annually in key markets and limited effective therapies.
Comparable ADC companies have seen 5-10x valuation increases post-Phase 1 data, suggesting significant upside potential within 12-18 months.
Multiple value inflection points anticipated as clinical milestones are reached over the next 18 months.
Latest events from Akari Therapeutics
- AKTX-101 advances toward mid-2027 trials amid financing needs and going-concern doubt.AKTX
Q3 2026 - Vote proposed to increase shares for equity incentives; Board recommends approval.AKTX
Proxy filing - Q2 net loss was $4.8M; cash at $7.7M after $8.6M raise, more funding needed for trials.AKTX
Q2 2026 - Early-stage oncology firm advancing novel ADCs, facing high risk and reliant on future capital.AKTX
Registration filing - Resale registration covers nearly 6 million ADSs from private placements and warrants.AKTX
Registration filing - Novel ADC platform with immune-activating PH1 payload shows strong preclinical synergy with checkpoint inhibitors.AKTX
Webull Corporate Connect: Virtual Biotech Investment Webinar - Pre-revenue biotech registers resale of 5.99M ADSs; proceeds from warrants to fund R&D.AKTX
Registration filing - Preclinical oncology firm seeks up to $25M via ADS sales to fund R&D, with high dilution risk.AKTX
Registration filing - Comprehensive AGM proxy covers governance, compensation, and major share issuance proposals.AKTX
Proxy filing - Comprehensive AGM proxy covers governance, compensation, and major capital authorizations.AKTX
Proxy filing